Procedure of the Loughborough Intermittent Shuttle Test. by Dominic Michael Rasp (19959412)

Subjects:

S1 Raw data - by Dominic Michael Rasp (19959412)

Subjects:

Development of the limb symmetry index (LSI) over the course of the LIST. by Dominic Michael Rasp (19959412)

Subjects:

Development of hamstring strength throughout the LIST. by Dominic Michael Rasp (19959412)

Subjects:

Summary of HSS and LSI during the LIST. by Dominic Michael Rasp (19959412)

Subjects:

S2 Raw data - by Dominic Michael Rasp (19959412)

Subjects:

Set-up of the optimized 90:20 Isometric Posterior Chain Test. by Dominic Michael Rasp (19959412)

Subjects:

Correlation between relative amounts of lipid species and number of days since the onset of symptoms among COVID-19 cases. by Spela Kokelj (8356644)

Subjects:

Correlation between protein abundances and R_5-20 z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (... by Spela Kokelj (8356644)

Subjects:

General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

Subjects:

Distribution of average relative amounts of lipid classes. by Spela Kokelj (8356644)

Subjects:

Flow chart on the inclusion and drop out of patients. by Spela Kokelj (8356644)

Subjects:

Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

Subjects:

Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Among them, W₃BipY₈-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W₃BipY₈ but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W₃BipY₈. …”

Loss of life expectancy that would result if colorectal cancer missed in 2011 had been diagnosed in 2011 (unit: years). by Hiroaki Saito (24514)

Subjects:

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Subjects:

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

Subjects:

Loss of life expectancy by age group and stage of colorectal cancer and change if detected after one year. by Hiroaki Saito (24514)

Subjects:

Estimated distribution of colorectal cancer stage among patients assumed to have missed diagnosis in 2011 (unit: persons). by Hiroaki Saito (24514)

Subjects: